



**Report of the third quarter (Q3) to the Shareholders
for the fiscal year 2006**

For the quarter ended December 31, 2005

including the comparative for the quarter ended December 31, 2004

ADK

Message to the Shareholders

Dear Shareholders:

During the quarter ended December 31, 2005, DIAGNOS focused its efforts on finishing the compilation of the large data set relating to mineral exploration acquired from the Quebec government. By the end of the quarter, DIAGNOS had analyzed exploration data consisting of over three billion data points and was able to establish a clear path for its strategy of acquiring exploration properties in Quebec.

In addition to providing consulting services to the mineral exploration industry, DIAGNOS will use the data acquired from the Quebec and other governments to identify attractive mineral properties which are available for staking. Once acquired, interests in these mining claims will be offered to companies engaged in mineral exploration in consideration for exploration expenditures. Accordingly, the Company intends to lever its technology, with minimal additional investment, into royalties or participation in commercial partnerships where these new partnerships will initially fund all of the exploration expenditures.

DIAGNOS plans to acquire its first mining claims in the fourth quarter and will most likely sign commercial partnership agreements during the fourth quarter.



André Larente
President

February 27, 2006

These mining claims have been identified by our team of scientists.

Furthermore, DIAGNOS is working with several consulting companies to enable a faster market penetration in the natural resource market and to establish long term relationships.

We are collaborating with companies in other industry sectors where we have identified applications for our technology. Because of its unique expertise in the field of artificial intelligence, DIAGNOS is getting increasing recognition of its capabilities world wide.

As examples, we are working with eRadiologiste, a Quebec based medical team in the area of advanced analytics for cancer detection. We are also working with Polyphonic, a Spanish company in the field of song analysis, to assess the market potential of new artists.

All these new applications require advanced analytics inherent in our technology using artificial intelligence to determine the outcome.

DIAGNOS inc.

Management Discussion and Analysis

DIAGNOS inc. (TSX Venture Exchange: ADK) is a Canadian software corporation that develops and sells knowledge extraction software. DIAGNOS is demonstrating a new dimension in analyzing data, text and images simultaneously in a commercial environment.

You will find more information concerning DIAGNOS inc. by consulting SEDAR Web site at www.sedar.com.

Notice to readers

The following discussion, effective as of February 27, 2006, analyses the current financial situation of the Corporation as of December 31, 2005 and should be read with the interim consolidated financial statements and accompanying notes, which are presented for financial information and conducted in accordance with generally accepted Canadian standards. The currency used is the Canadian dollar.

The attached unaudited interim consolidated financial statements have been reviewed by the Corporation's external auditors. The accompanying notes are an integral part of the interim consolidated financial statements.

Forward-looking statements

This MD&A contains certain forward-looking statements with respect to the Corporation. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. We consider the assumptions on which these forward-looking statements are based to be reasonable, but caution the reader that these assumptions regarding future events, many of which are beyond our control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect us. These risks and uncertainties include risks associated with market acceptance, competitive developments and other factors. Except for ongoing obligations under securities laws to disclose all material information to investors, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Summary of quarterly results

	Fiscal Year 2006			Fiscal Year 2005			Fiscal Year 2004	
	Q3	Q2	Q1	Q4	Q3	Q2	Q1	
	Dec. 31 2005	Sept. 30, 2005	June 30, 2005	March 31, 2005	Dec. 31, 2004	Sept. 30, 2004	June 30, 2004	March 31, 2004
	\$	\$	\$	\$	\$	\$	\$	
Revenue	90,419	172,667	180,082	(44,497)	47,775	4,504	103,964	150,000
Net income (Loss)	(297,680)	(140,477)	(80,801)	(382,341)	(415,797)	(542,262)	(427,043)	(67,753)
Earnings per share	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	(0.02)	(0.02)	(0.00)

Financial highlights

	Fiscal Year 2005	Fiscal Year 2004	Fiscal Year 2003
	\$	\$	\$
Revenue	111,746	387,720	128,619
Income taxes	-	-	-
Net income (Loss)	(1,746,088)	(130,059)	(762,983)
Earnings per share	(0.07)	(0.01)	(0.07)
Total assets	376,770	711,902	250,856
Total long-term liabilities	215,159	840,656	783,646

Revenue

Revenue for the third quarter ended December 31, 2005 was \$90,419 compared to revenue generated in the quarter ended December 31, 2004, of \$47,775. Our total customer count has not changed and we expect, during the next quarters, to sign agreements with several new customers. DIAGNOS' total contract bookings since the beginning of the year amount to \$595,000. Our billing backlog (contracted but unbilled) is approximately \$150,000. Our nine-month revenue for the period ended December 31, 2005 is \$443,169 a 184% increase compared to \$156,243 for the 2004 comparative period.

Expenses

The general, sales and administrative expenses for the third quarter ended December 31, 2005 grew by \$99,244, an increase of 40%. The main reasons are: consulting services, legal fees and increases in salaries. Furthermore, the Corporation relocated during the quarter and incurred additional expenses related to this move.

Research and Development

The Corporation has incurred \$33,656 in research and development costs during the quarter, an increase of \$6,165 compared to the previous quarter. This increase is mainly due to the fact that we hired a consultant for our client from the security sector.

DIAGNOS inc.

Management Discussion and Analysis (Cont'd)

Net loss

During the third quarter ended December 31, 2005, the Corporation has incurred a net loss of \$297,680 (\$0.01 per share) compared to a net loss of \$415,797 (\$0.01 per share) for the period ended December 31, 2004. This decrease in net loss compared to the quarter ended December 31, 2004 is mainly due to lower R&D expenditures. The Corporation's main R&D project for the development of its AI (Artificial Intelligence) engine was completed in the previous fiscal year. Our current R&D activities are related to customer implementations. During the third quarter ended December 31, 2005, the Corporation's internal activities were focused on finalizing the analysis of the Quebec data set acquired. DIAGNOS processed over three billion data points to enable the recognition of the signatures of copper, gold and zinc drill holes for the identification of target exploration zones.

Financing activities

During the third quarter ended December 31, 2005, \$332,827 were received from the proceeds of the private placement announced in the second quarter of this fiscal year. There were no warrants exercised during the quarter.

Working capital

As at December 31, 2005, the working capital of the Corporation was \$746,639 compared to \$99,756 on March 31, 2005. DIAGNOS anticipates revenues that will cover a portion of the expenses incurred during the following quarters and the remaining will come from cash on hand. If for any reason DIAGNOS should require additional cash to pay expenses, the Corporation would raise additional cash from a private placement to its existing Shareholders or new investors. The Corporation also anticipates purchasing additional assets in the form of exploration claims for approximately \$50,000 during the next three quarters.

Share information

As at December 31, 2005, the outstanding shares are common shares or shares attached to common shares:

Common shares	33,693,019
Convertibles	
Warrants	13,611,332
Options on shares	3,308,949
Total	<u>50,613,300</u>

Significant accounting policy

The Corporation recognizes stock-based compensation and other stock-based payments as compensation expense determined in accordance with the Black & Scholes valuation model, with a corresponding accretion to contributed surplus.

Outlook

The Corporation's AI engine will be the driving force behind building new applications for vertical markets. Our natural resource application CARDS (Computer Aided Resource Detection Software) was our first vertical market. The Corporation is focused on delivering solutions for the natural resource market and also on building a royalty based business. This will be accomplished by the acquisition of land and taking participation with existing clients on new projects. Secondly, the Corporation acquired data from several sources including the Quebec and Ontario governments that will be used to identify potential claims for purchase.

The Corporation delivered a solution for the Oil & Gas exploration market during its second quarter. This new application generated our first customer in the Oil & Gas market and we will be increasing our sales activities in the Oil & Gas market in quarters to come. Finally, the Corporation is pursuing other markets that require AI technology to resolve complex problems within different industries. The Corporation signed a development contract related to the security market with Optosecurity during the second quarter. This development contract is continuing and should be finished by the end of the calendar year of 2006. DIAGNOS has been approached by other AI companies from Spain and other countries to create partnership covering North America. The Corporation is working with a group of radiologists based in the Province of Quebec to continue the original work done by DIAGNOS in the medical field. Our MAMMO application for breast cancer identification is an example of the work that could be back for our development department.

All these new applications will re-enforce DIAGNOS' market penetration and isolate the Corporation from any market should there be an economic fluctuation.

Risk analysis

Several business risks exist such as the market adoption of AI technology, the Corporation's ability to hire and retain top scientific resources and our ability to convince customers in these new vertical markets of the benefit of our technology and its results. The Corporation also relies on its Shareholders to provide funding, in the event it should experience shortfalls, to sustain continued operations.

DIAGNOS inc.

Interim Consolidated Balance Sheets

	As at December 31, 2005	As at March 31, 2005
	(Unaudited)	(Audited)
	<u>\$</u>	<u>\$</u>
ASSETS		
Current assets		
Cash and cash equivalents	736,492	258,008
Amounts receivable (Note 3)	182,344	50,128
Prepaid expenses (Note 4)	1,506	6,779
	<u>920,342</u>	<u>314,915</u>
Capital assets (Note 5)	64,674	45,640
Intangible assets (Note 6)	<u>15,074</u>	<u>16,215</u>
	<u>1,000,090</u>	<u>376,770</u>
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (Note 7)	<u>173,703</u>	<u>215,159</u>
SHAREHOLDERS' EQUITY (Shareholders' deficit)		
Share capital (Note 8)	8,961,102	7,869,860
Contributed surplus (Note 9)	179,126	86,634
Deficit	<u>(8,313,841)</u>	<u>(7,794,883)</u>
	<u>826,387</u>	<u>161,611</u>
	<u>1,000,090</u>	<u>376,770</u>

SEE ACCOMPANYING NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS.

Approved on behalf of the Board of Directors



André Larente
Director



Me David Crevier
Secretary

DIAGNOS inc.

Interim Consolidated Statements of Income

	For the quarters ended December 31		For the nine-month periods ended December 31	
	2005 (Unaudited) \$	2004 (Unaudited) \$	2005 (Unaudited) \$	2004 (Unaudited) \$
Revenue	90,419	47,775	443,169	156,243
Expenses				
General, sales and administrative	349,222	249,978	841,715	835,560
Research and development	33,656	207,887	102,569	695,719
Amortization of capital assets	3,011	4,376	11,494	13,472
Amortization of intangible assets	1,981	995	6,152	3,431
Financial charges	229	336	197	13,015
	388,099	463,572	962,127	1,561,197
Net income (Loss) for the period	(297,680)	(415,797)	(518,958)	(1,404,954)
Basic and diluted loss per share	(0.01)	(0.01)	(0.02)	(0.05)
Basic weighted average number of shares outstanding	33,562,584	28,886,017	30,792,187	26,039,860

SEE ACCOMPANYING NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS.

DIAGNOS inc.

Interim Consolidated Statements of Deficit

	For the quarters ended December 31		For the nine-month periods ended December 31	
	2005	2004	2005	2004
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	\$	\$	\$	\$
Balance at the beginning of the period	<u>(8,016,161)</u>	<u>(7,037,952)</u>	<u>(7,794,883)</u>	<u>(6,046,133)</u>
Add:				
Net income (Loss)	(297,680)	(415,797)	(518,958)	(1,404,954)
Interest paid on the component Shareholders' equity of convertible debentures	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,662)</u>
	<u>(297,680)</u>	<u>(415,797)</u>	<u>(518,958)</u>	<u>(1,407,616)</u>
Balance at the end of the period	<u>(8,313,841)</u>	<u>(7,453,749)</u>	<u>(8,313,841)</u>	<u>(7,453,479)</u>

SEE ACCOMPANYING NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS.

DIAGNOS inc.

Interim Consolidated Statements of Cash Flows

	For the quarters ended December 31		For the nine-month periods ended December 31	
	2005	2004	2005	2004
	(Unaudited) \$	(Unaudited) \$	(Unaudited) \$	(Unaudited) \$
Cash flows from operating activities				
Net income (Loss) for the period	(297,680)	(415,797)	(518,958)	(1,404,954)
Items not affecting cash and cash equivalents				
Amortization of capital assets	3,011	4,376	11,494	13,472
Amortization of intangible assets	1,981	995	6,152	3,431
Write-down of capital assets	8,411	-	8,411	-
Write-down of intangible assets	912	-	912	-
Issuance of shares under the payment of interest on debentures	-	-	-	13,341
Stock-based compensation expense	33,212	21,355	92,492	63,541
	<u>47,527</u>	<u>26,726</u>	<u>119,461</u>	<u>93,785</u>
	(250,153)	(389,071)	(399,497)	(1,311,169)
Net change in non-cash operating working capital items	<u>(17,039)</u>	<u>(32,225)</u>	<u>(168,399)</u>	<u>(244,528)</u>
	<u>(267,192)</u>	<u>(421,296)</u>	<u>(567,896)</u>	<u>(1,555,697)</u>
Cash flows from financing activities				
Issuance of capital stock – net of related issuance expenses	332,827	-	1,091,242	2,049,953
Subscription of capital stock	-	-	-	-
Reimbursements of convertible debentures	-	-	-	(535,000)
	<u>332,827</u>	<u>-</u>	<u>1,091,242</u>	<u>1,514,953</u>
Cash flows from investing activities				
Additions to capital assets	(32,100)	(2,894)	(38,940)	(12,491)
Additions to intangible assets	(3,552)	-	(5,922)	-
	<u>(35,652)</u>	<u>(2,894)</u>	<u>(44,862)</u>	<u>(12,491)</u>
Net change in cash and cash equivalents	29,983	(424,190)	478,484	(53,235)
Cash and cash equivalents – Beginning of the period	<u>706,509</u>	<u>908,207</u>	<u>258,008</u>	<u>537,252</u>
Cash and cash equivalents – End of the period	<u>736,492</u>	<u>484,017</u>	<u>736,492</u>	<u>484,017</u>

SEE ACCOMPANYING NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS.

DIAGNOS inc.

Notes to Interim Consolidated Financial Statements

As at December 31, 2005 and March 31, 2005

1. Statutes and nature of activities

The shares of the Corporation are listed on the TSX Venture Exchange. DIAGNOS inc. develops and markets data mining software. The Corporation designed, developed and markets MCubiX, a data mining software suite capable of extracting knowledge from historical data - in the form of images, text or traditional databases - and making predictions that improve business processes and decision making ability. CARDS (Computer Aided Resource Detection Software), the first vertical application, is dedicated to the natural resources market and can be applied to several sectors of prospecting, such as diamond, gold, zinc, copper and the oil and gas.

2. Summary of significant accounting policies

a) Use of estimates

The preparation of interim consolidated financial statements in accordance with Canadian generally accepted accounting principles requires management to make estimates that affect the amounts of assets and liabilities reported in the interim consolidated financial statements. Those estimates also affect the disclosure of contingencies at the date of the financial statements and the reported amounts of revenues and expenses during the period. Significant estimates include tax credits recoverable, the useful lives of capital assets and intangible assets and certain accrued liabilities. Actual results could differ from those estimates.

b) Consolidation

These interim consolidated financial statements include the accounts of the Corporation and those of its wholly-owned subsidiary, DMS & Technologies Inc.

c) Foreign currency translation

The accounts are remeasured into the functional currency using the temporal method. Under this method, monetary assets and liabilities are remeasured at the exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are remeasured at historical rates. Revenues and expenses are remeasured at the average rate for the period. Income and losses resulting from remeasurement are reflected in the statement of income.

d) Government assistance

The Corporation obtained tax credits from the government of Quebec according to the research and development concerning the conception of software. The aforementioned tax credits thus obtained were entered in deduction of the expenses.

e) Revenue recognition

The revenues from software are generally recognized as the delivery was made in accordance with the methods contained in a sale contract and that the risks and the significant advantages inherent in the property are transferred to the customer.

f) Cash and cash equivalents

Cash and cash equivalents consist of cash on hand and balance with banks as well as all highly liquid short-term investments having a term of less than three months as the acquisition date.

g) Capital assets and amortization

Capital assets are recorded at cost less accumulated amortization and related tax credits. Amortization is calculated using the declining balance method at the following annual rates:

	<u>Annual rates</u>
Office furniture and equipment	- 20%
Computer equipment	- 50%

h) Intangible assets and amortization

- i) The license has been amortized using the straight-line method over the estimated useful life of this asset, which was three years.
- ii) The mining assets, consisting of prospecting concessions, are amortized using the straight-line method over their useful life, which is two years.
- iii) Software is amortized using the declining balance method at the annual rate of 50%.

DIAGNOS inc.

Notes to Interim Consolidated Financial Statements (Cont'd)

2. Summary of significant accounting policies (Cont'd)

i) Income taxes

The Corporation provides for income taxes using the liability method of tax allocation. Under this method, future income tax assets and liabilities are determined based on deductible or taxable temporary differences between financial statement values and tax values of assets and liabilities using enacted income tax rates expected to be in effect for the year in which the differences are expected to reverse.

The Corporation establishes a valuation allowance against future income tax assets if, based on available information, it is more likely than not that some or all the future income tax assets will not be realized.

j) Research and development expenses

All expenses related to development activities, which do not meet generally accepted criteria for deferral, and research are expensed as incurred. Development expenses, which meet generally accepted criteria for deferral, are capitalized and amortized against income over the estimated period of benefit.

k) Loss per share

The loss per share is determined using the weighted average number of common shares outstanding during the year.

During the period, only the warrants and stock options whose exercise price was equal or lower than the average stock market during the exercise were taken into account.

The loss diluted by share, which is calculated according to the method of the repurchase of share, is equal to the basic loss by share because of the anti-dilution effect of the stock option plan.

l) Share issue expenses

Share issue expenses have been applied against the proceeds from the issuance of share capital.

m) Stock-based compensation plan

The Corporation maintains a stock-based compensation plan, which is described in note 8. Stock-based compensation is charged to income as compensation expense using the Black & Scholes valuation model, with a corresponding credit to contributed surplus. Any consideration from plan participants upon the exercise of stock options is credited to share capital.

DIAGNOS inc.

Notes to Interim Consolidated Financial Statements (Cont'd)

	As at December 31, 2005	As at March 31, 2005		
	(Unaudited)	(Audited)		
	<u>\$</u>	<u>\$</u>		
3. Amounts receivable				
Customers	215,354	70,702		
Commodity taxes	-	12,436		
Others	<u>10,200</u>	<u>10,200</u>		
	225,554	93,338		
Allowance for doubtful accounts	<u>43,210</u>	<u>43,210</u>		
	<u>182,344</u>	<u>50,128</u>		
4. Prepaid expenses				
Prepaid insurance	678	6,779		
Others	<u>828</u>	<u>-</u>		
	<u>1,506</u>	<u>6,779</u>		
5. Capital assets				
	Cost	Accumulated amortization	Net value	Net value
	<u>\$</u>	<u>\$</u>	<u>\$</u>	<u>\$</u>
Office furniture and equipment	65,045	28,396	36,649	28,220
Computer equipment	<u>164,778</u>	<u>136,753</u>	<u>28,025</u>	<u>17,420</u>
	<u>229,823</u>	<u>165,149</u>	<u>64,674</u>	<u>45,640</u>
6. Intangible assets				
	Cost	Accumulated amortization	Net value	Net value
	<u>\$</u>	<u>\$</u>	<u>\$</u>	<u>\$</u>
License	239,812	239,812	-	-
Mining assets	3,552	296	3,256	-
Software	<u>37,059</u>	<u>25,241</u>	<u>11,818</u>	<u>16,215</u>
	<u>280,423</u>	<u>265,349</u>	<u>15,074</u>	<u>16,215</u>
7. Accounts payable and accrued liabilities				
Accounts payable and accrued liabilities		70,637	142,014	
Salaries and fringe benefits		74,885	47,347	
Commodity taxes		3,363	-	
Others		<u>24,848</u>	<u>25,798</u>	
		<u>173,703</u>	<u>215,159</u>	

DIAGNOS inc.**Notes to Interim Consolidated Financial Statements (Cont'd)****8. Share capital (Cont'd)**

The compensation cost that has been charged against income is \$33,212 for the quarter ended December 31, 2005, with a corresponding credit to contributed surplus in the Shareholders' equity.

These options will expire on different dates. The prior grants at June 3, 2004 were subject to an exercise period ranging between one and a half and five years. Options granted from June 3, 2004 vest at 33.33% per year, beginning twelve months after the date of grant.

Stock warrants

- a) In the process of a private placement, the Corporation issued 2,500,000 warrants entitling the holder to purchase one common share at the price of \$0.14 per share. They will expire on dates ranging from September 7, 2006 and December 14, 2006.

	<u>Stock warrants</u>	<u>Exercise price</u>
Outstanding as at September 30, 2005	2,500,000	\$0.14
Exercised	-	-
Outstanding as at December 31, 2005	<u>2,500,000</u>	<u>\$0.14</u>

- b) In the process of a private placement, the Corporation issued 8,000,000 warrants entitling the holder to purchase one common share at the price of \$0.20 per share. They will expire on dates ranging from August 8, 2006 and December 10, 2006.

	<u>Stock warrants</u>	<u>Exercise price</u>
Outstanding as at September 30, 2005	7,278,000	\$0.20
Exercised	-	-
Outstanding as at December 31, 2005	<u>7,278,000</u>	<u>\$0.20</u>

- c) In the process of a private placement, the Corporation issued 1,833,332 warrants entitling the holder to purchase one common share at the price of \$ 0.40 per share. They will expire on August 30, 2006.

	<u>Stock warrants</u>	<u>Exercise price</u>
Outstanding as at September 30, 2005	1,833,332	\$0.40
Exercised	-	-
Outstanding as at December 31, 2005	<u>1,833,332</u>	<u>\$0.40</u>

- d) In the process of a private placement, the Corporation issued 2,000,000 warrants entitling the holder to purchase one common share at the price of \$ 0.35 per share. They will expire on October 4, 2007.

	<u>Stock warrants</u>	<u>Exercise price</u>
Issued on October 4, 2005	2,000,000	\$0.35
Exercised	-	-
Outstanding as at December 31, 2005	<u>2,000,000</u>	<u>\$0.35</u>

DIAGNOS inc.

Notes to Interim Consolidated Financial Statements (Cont'd)

	As at December 31, 2005	As at March 31, 2005
	(Unaudited)	(Audited)
	<u>\$</u>	<u>\$</u>
9. Consolidated contributed surplus		
Balance at beginning of the period	86,634	-
Add: Accretion on stock-based compensation	<u>92,492</u>	<u>86,634</u>
Balance at end of the period	<u>179,126</u>	<u>86,634</u>

10. Financial instruments**a) Fair value**

Cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities are financial instruments whose fair value approximates their carrying value due to their short-term maturity.

b) Credit risk

Financial instruments, which potentially subject the Corporation to concentrations of credit risk, consist primarily of cash and cash equivalents. These financial instruments are held with high-credit quality financial institutions. Consequently, management considers the concentration of risk related to cash and cash equivalents to be minimal.

c) Interest rate risk

As at December 31, 2005, the Corporation's exposure to interest rate risk is summarized as follows:

Cash and cash equivalents	- Fixed and variable interest rate
Amounts receivable	- Non-interest bearing
Accounts payable and accrued liabilities	- Non-interest bearing

General information

Stock Exchange Listing

Shares of DIAGNOS inc. are listed on the TSX Venture Exchange under the symbol ADK.

Transfer Agents and Registrar

Computershare Trust Company of Canada
1500, University Street
Suite 7001
Montréal, Québec
H3A 3S8

Auditors

Potvin Magnan & Associés Inc., CA
200, MacDonald Street
Suite 302
Saint-Jean-sur-Richelieu, Québec
J3B 8J6

Legal Counsel

Colby Monet Demers Delage & Crevier
Tour McGill College
1501, McGill College Avenue
Suite 2900
Montréal, Québec
H3H 3M8

Electronic Delivery

The Shareholders of DIAGNOS inc. can elect to receive DIAGNOS' documents (such as Quarterly and Annual Reports and the Proxy Circular) in electronic form on the Internet rather than in hard copy by mail. Shareholders wishing to use this service should contact Computershare Trust Company of Canada.

Directors

W. Brian Edward
Chairman of the Board

David Crevier, Secretary

André Larente, Director

Olivier Lerolle, Director

Livia Masnaghetti, Director

Timothy R. Murdoch, Director

Investor Relations

If you have inquiries, please visit DIAGNOS' Web site at www.diagnos.ca or contact:

André Larente
President and Chief Executive Officer

DIAGNOS inc.

7005, Taschereau Boulevard
Suite 340
Brossard, Québec
J4Z 1A7

Telephone: (450) 678-8882
Toll free: (877) 678-8882
Fax: (450) 678-8119
www.diagnos.ca

Definition

In this report all currencies are in Canadian dollars unless specified.

Additional copies are available upon request.

Un exemplaire français du présent rapport trimestriel est disponible sur demande.